Last reviewed · How we verify
Investigational Cancer Drug
At a glance
| Generic name | Investigational Cancer Drug |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- Electrochemotherapy of Posterior Resection Surface for Lowering Disease Recurrence Rate in Pancreatic Cancer (PanECT Study) (NA)
- Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (PHASE1, PHASE2)
- Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma (PHASE2)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- TILs Therapy for Multiple Primary Early-Stage NSCLC (EARLY_PHASE1)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational Cancer Drug CI brief — competitive landscape report
- Investigational Cancer Drug updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI